Literature DB >> 15533073

Generalized necrobiosis lipoidica treated with a combination of split-thickness autografting and immunomodulatory therapy.

Deborah L Cummins1, Kim M Hiatt, Daniel Mimouni, Craig A Vander Kolk, Bernard A Cohen, Carlos H Nousari.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15533073     DOI： 10.1111/j.1365-4632.2004.02120.x

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN： 0011-9059            Impact factor:   2.736


× No keyword cloud information.
  4 in total

1.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; P Emery; E C Keystone; M H Schiff; P L C M van Riel; M E Weinblatt; M H Weisman
Journal:  Ann Rheum Dis       Date:  2006-11       Impact factor: 19.103

Review 2.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; J Sieper; P Emery; E C Keystone; M H Schiff; P Mease; P L C M van Riel; R Fleischmann; M H Weisman; M E Weinblatt
Journal:  Ann Rheum Dis       Date:  2007-11       Impact factor: 19.103

3.  Ulcerative Necrobiosis Lipoidica: Is There a Place for Anti-TNFα Treatment?

Authors:  Rita Guedes; Inês Leite; Armando Baptista; Natividade Rocha
Journal:  Case Rep Med       Date:  2012-05-23

4.  The role of anti-tumour necrosis factor in wound healing: A case report of refractory ulcerated necrobiosis lipoidica treated with adalimumab and review of the literature.

Authors:  Vijay Kumari Sandhu; Afsaneh Alavi
Journal:  SAGE Open Med Case Rep       Date:  2019-10-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.